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The South Asian population, numbered at 1.8 billion, is estimated to comprise around
20% of the global population and 1% of the American population, and has one
of the highest rates of cardiovascular disease. While South Asians show increased
classical risk factors for developing heart failure, the role of population-specific genetic
risk factors has not yet been examined for this group. Hypertrophic cardiomyopathy
(HCM) is one of the major cardiac genetic disorders among South Asians, leading to
contractile dysfunction, heart failure, and sudden cardiac death. This disease displays
autosomal dominant inheritance, and it is associated with a large number of variants
in both sarcomeric and non-sarcomeric proteins. The South Asians, a population with
large ethnic diversity, potentially carries region-specific polymorphisms. There is high
variability in disease penetrance and phenotypic expression of variants associated
with HCM. Thus, extensive studies are required to decipher pathogenicity and the
physiological mechanisms of these variants, as well as the contribution of modifier genes
and environmental factors to disease phenotypes. Conducting genotype-phenotype
correlation studies will lead to improved understanding of HCM and, consequently,
improved treatment options for this high-risk population. The objective of this review is to
report the history of cardiovascular disease and HCM in South Asians, present previously
published pathogenic variants, and introduce current efforts to study HCM using induced
pluripotent stem cell-derived cardiomyocytes, next-generation sequencing, and gene
editing technologies. The authors ultimately hope that this review will stimulate further
research, drive novel discoveries, and contribute to the development of personalized
medicine with the aim of expanding therapeutic strategies for HCM.
Keywords: hypertrophic cardiomyopathy, South Asians, β-myosin heavy chain, MYH7, cardiac myosin binding
protein-C, MYPBC3
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THE CARDIOVASCULAR DISEASE
DILEMMA IN SOUTH ASIAN AMERICANS
Although most cardiovascular disease (CVD) is preventable
(Yusuf et al., 2004), it is the leading cause of death worldwide. The
burden of CVD mortality is greatest in lower-income countries,
yet is responsible for 1 in 4 deaths in the United States (Gupta
et al., 2016). The South Asian subcontinent contains 20% of
the world’s population, yet accounts for about 60% of CVD
worldwide. A map of this region, which includes the modern-day
countries of Afghanistan, Bangladesh, Bhutan, India, Nepal, the
Maldives, Pakistan, and Sri Lanka (Hajra et al., 2013), is shown
in Figure 1. An estimated 1.8 billion people live in the South
Asian region, and comprise one-fifth of the world’s population.
South Asians (SA) have a significantly increased risk of CVD
when compared to their European counterparts (Anand et al.,
2000; Yusuf et al., 2004; Fernando et al., 2015). Numerous studies
have tried to account for this, assessing both traditional and
non-traditional risk factors with inconsistent results (Chaturvedi,
2003; Palaniappan et al., 2010; Fernando et al., 2015). When
considered together, risk factors alone do not account for the fact
that SA immigrant populations are 3–5 times more likely to die
of CVD than other ethnic groups (Gupta et al., 2006).
To date, the 2006 National Health Interview Survey is the
only nationally representative data for obesity, CVD, and diabetes
in Asian Americans (Barnes et al., 2008). However, the survey
is limited in scope by self-reported collection measures, small
sample size, and lack of long-term data (Mohanty et al., 2005;
FIGURE 1 | Map of South Asia. South Asia, sometimes referred to as the
Indian subcontinent, includes the modern day countries of Afghanistan,
Bangladesh, Bhutan, India, Nepal, the Maldives, Pakistan, and Sri Lanka.
Myanmar, shown in the figure, is usually not included in South Asia except for
population studies by the United Nations. Map modified from wikimedia
commons South_Asia_(ed)update.PNG. An estimated 1.8 billion people live in
this region, comprising one-fifth of the world’s population and three-fifths of the
global cardiovascular disease burden.
Narayan et al., 2010; Holland et al., 2011). Another glaring
problem, especially when considering the existing interethnic
comparative CVD studies, is the grouping of this extremely
diverse population into the broad category of “Asian & Pacific
Islander.” Genetic, environmental, and behavioral differences
exist among ethnic subpopulations of this group, and such
differences contribute to differential health outcomes (Graham
et al., 2006). More accurate epidemiology data and risk models
could be generated if these groups were disaggregated (Mohanty
et al., 2005; Narayan et al., 2010; Holland et al., 2011; Gopal and
Usher-Smith, 2016).
Within the last 40 years, changes in immigration policies
have paved the way for dramatic migration of SA into the
United States. SA were the fastest growing ethnic group in the
United States between the years 2000 and 2010 (Gezmu et al.,
2014). Currently, there are an estimated 3.5 million SA living
in America, meaning that they constitute around 1% of the
American population (Tang et al., 2012). Since its inception in
2010, the Mediators of Atherosclerosis in South Asians Living in
America (MASALA) Study has examined cardiometabolic risk
and CVD outcomes in South Asian Americans on a longitudinal
basis (Kanaya et al., 2013). This groundbreaking study will
undoubtedly generate comprehensive, population-specific data
for this at-risk population. A pilot study completed in 2015, called
the South Asian Heart Lifestyle Intervention (SAHELI) Study,
initiated efforts to deliver culturally sensitive educational material
to underserved SA at risk for CVD. However, despite these recent
efforts health disparities continue to exist for this American
subpopulation (Fernando et al., 2015). The paucity of cardiac
disease data for Asian Americans is a barrier to addressing one
of the most concerning public health issues of our time.
HYPERTROPHIC CARDIOMYOPATHY, A
TREATABLE FORM OF CVD
The Cardiomyopathies
Cardiomyopathies are a heterogeneous group of diseases of
the myocardium associated with mechanical and/or electrical
dysfunction. They usually exhibit inappropriate ventricular
hypertrophy or dilatation and are due to a variety of causes that
are commonly genetic (Elliott et al., 2008). Cardiomyopathies
either are confined to the heart or are part of generalized
systemic disorders, often leading to cardiovascular death or
progressive heart failure-related disability (Maron et al., 2006).
Cardiomyopathies are present in all populations, with ethnicity,
age, and gender affecting disease severity and expression
(McNally et al., 2015). The three main types of cardiomyopathy
affecting the left ventricle are hypertrophic cardiomyopathy
(HCM), dilated cardiomyopathy (DCM), and restrictive
cardiomyopathy (RCM) (Elliott et al., 2008). Prototypical cases
of HCM show abnormally large and misaligned myocytes
localized to the interventricular septum and increased fibrosis
(Gersh et al., 2011). The thickened and stiff ventricle reduces
the compliance of the heart muscle, decreases preload, and
contributes to diastolic heart failure (Jacoby et al., 2013; Hensley
et al., 2015). On the other end of the spectrum, typical DCM cases
show chamber volume dilatation and thin walls, which reduces
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contractile force, and causes systolic heart failure. In RCM, which
is the least common of the cardiomyopathies, patients typically
have normal wall thickness (Elliott et al., 2008; Gersh et al., 2011).
A diagnosis of RCM is made when left ventricular pressure is
pathologically increased at normal or reduced chamber volumes
due to excessive fibrotic accumulation. The structural differences
between a normal heart and those affected by DCM, HCM, or
RCM are illustrated in Figure 2. Although the typifying cases of
cardiomyopathies are clearly differentiated, it should be noted
that the clinical presentation of end stage cardiomyopathy can
overlap significantly.
Overview of Familial HCM
Familial HCM is the most common inherited cardiac disease
and affects 1 in every 500 people worldwide (Maron et al.,
2014). Since its first description in the 1950s, much progress has
been made in elucidating the extremely heterogeneous genetic,
morphogenic, and clinical profile of the disease (Elliott and
McKenna, 2009). Symptoms of HCM are variable in severity
and overlap with those of general CVD, including chest pain,
shortness of breath, lightheadedness, palpitations, fatigue, and
inability to perform vigorous exercise (Gersh et al., 2011).
Another devastating manifestation of HCM is sudden cardiac
death (SCD). Extensive left ventricular hypertrophy (LVH) in
the absence of another cause can confirm a diagnosis of HCM
(Brouwer et al., 2011). Non-parallel cell arrangement results
in a characteristic “whirling” pattern and likely contributes to
arrhythmogenicity in HCM patients. These histological changes
are typically accompanied by increased collagen deposition
and hyperplasia of microvasculature, pathologically narrowing
the lumen and leading to symptoms related to myocardial
ischemia (Shirani et al., 2000). HCM is typically classified as
obstructive or non-obstructive depending on chamber anatomy,
which determines the area through which blood can flow out
of the heart. Obstructive HCM is normally associated with
a worse prognosis due to the combined effects of systolic
and diastolic dysfunction (Maron et al., 2003). Left ventricular
outflow tract (LVOT) obstruction can result from a severely
hypertrophied interventricular septum and/or abnormal mitral
valve morphology (Nagueh and Mahmarian, 2006), as seen in
Figure 2. The dynamic nature of LVOT obstruction aids in
differentiation of HCM from other conditions in which LVH is
the result of chronic and fixed pressure overload (Jacoby et al.,
2013). LVOT obstruction, as well as other diagnostic hallmarks
of HCM, can be detected via non-invasive imaging techniques
such as echocardiography and cardiac MRI (Hensley et al., 2015)
and in some cases provoked by altering loading conditions of the
heart.
Treatment of HCM
As is typical for many forms of CVD, many current therapeutic
strategies for HCM try to alleviate symptoms and prevent
complications. Although once considered rare and terminal,
HCM has now emerged as a very treatable form of heart
disease (Maron et al., 2014). Due to the variety of available
surgical, pharmacological, electrical treatment options, HCM
mortality rates have dropped to 0.5% per year (Maron et al.,
2015). Beta-blockers and calcium channel blockers are used to
improve diastolic function in patients with HCM (Brouwer et al.,
2011; Hensley et al., 2015). Implantable cardiac defibrillators
in conjunction with anticoagulants control potentially life-
threatening arrhythmias and avoid SCD. Two common surgical
procedures performed in about 3% of obstructive HCM patients
are septal myectomy and alcohol septal ablation (Roma-
Rodrigues and Fernandes, 2014). Both techniques are very
successful at relieving LVOT obstruction and heart failure
symptoms and have excellent long-term prognoses (Gersh et al.,
2011; Jacoby et al., 2013; Maron et al., 2014). Early diagnosis
and treatment of HCM is key to preventing long-term chamber
remodeling and reducing the number of patients that advance to
end-stage heart failure.
POPULATION GENETICS OF HCM IN
SOUTH ASIANS
Genetic Susceptibility of South Asians
Modern humans first evolved in Africa 200,000 years ago and
dispersed about 100,000 years thereafter (Majumder, 2010).
Although details of the initial waves of people leaving Africa
have been debated, archeological and genetic evidence points to
a single South Asian dispersal route (Kivisild et al., 2003; Mellars,
2006; Majumder, 2010). From there, people populated the rest
of Eurasia and then the world. Thus, using European or East
Asian populations, who are genetic descendants of South Asians,
to predict risk for their genetic ancestors is, by definition, an
inappropriate model. The strong cultural ties of SA in America,
and the tradition of consanguineous marriage offer unique
opportunities to study genetics and allele frequencies of this
population (Waldmüller et al., 2003). In particular, India’s history
of founder events predicts a high rate of recessive disease (Reich
et al., 2009) and could act as a model for studying how genetic
variation affects disease expression. Prioritization of South Asian
Americans for screening of such recessive disease is a largely
unexplored opportunity for researchers and clinicians alike. This
also requires that such studies be carried out specifically in
SA genomes, and not in comparison with Caucasian or East
Asian genomes that share very few of these region-specific
variants.
Genetic Heterogeneity of HCM
Recent advances in genetic sequencing techniques and the
potential of therapeutic intervention in families with inherited
cardiomyopathies have garnered this group of disorders much
attention in the scientific community. Commercially available
genetic screens are available to supplement a clinical diagnosis,
and they have a mutation detection rate of 50–60% (Golbus
et al., 2012). Genetic testing is recommended for at-risk
family members who may also harbor a “private” familial
variant (Gersh et al., 2011; Das et al., 2014). Once a
variant is found, however, interpretation of its pathogenicity
can be complicated. For example, distinguishing pathogenic
variants from rare non-pathogenic variants or variants of
unknown significance has proven difficult (Roma-Rodrigues and
Fernandes, 2014). Currently, researchers have more variants of
unknown significance than they can examine (Das et al., 2014). It
would be impractical to study rare variants clinically, but recent
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FIGURE 2 | Anatomical cross-sections of hearts with various forms of cardiomyopathy. (A) Arrows outline the path of blood flow in a healthy heart. Blue
corresponds to the deoxygenated venous return to the heart. Red corresponds to the oxygenated blood in the left side of the heart. After oxygen saturation in the
lungs, blood is directed from the left atrium (LA) through the mitral valve (MV) into the left ventricle (LV). Then, it is pumped through the aorta to the rest of the body. (B)
A typical enlarged heart seen in DCM, with thin and stretched walls and large chamber volumes. (C) A typical heart seen in HCM, with generalized hypertrophy and
reduced size of the LV chamber. Increased wall thickness of the interventricular septum and protrusion of the MV into the outflow path contribute to left ventricular
outflow tract obstruction (LVOTO). (D) A typical heart seen in RCM with ventricular walls of normally thickness. The walls are stiffened by increased fibrotic deposition,
which is signified by darker shading.
large-scale sequencing projects have allowed statistical analysis
of these variants (Lopes et al., 2013b). Typically, pathogenicity
is estimated via in silico predictive algorithms that estimate a
mutation’s effect on protein structure and function and assess
it in terms of evolutionary conservation (Ritchie and Flicek,
2014; Richards et al., 2015). While the use of multiple software
programs to assess pathogenicity or a bioinformatics “pipeline”
is recommended (Rehm et al., 2013), such programs still lack
clinical data as input, making them insufficient for diagnostic
purposes. Continued re-evaluation of all variants, even those
previously considered benign, is necessary as predictive testing
techniques continue to advance (Das et al., 2014; Richards et al.,
2015). Family segregation studies and cellular/animal models are
also options for studying pathogenicity of rare variants, but they
are time-consuming and expensive.
Necessity of Population-Specific Genetic
Data for HCM
Apart from rare private familial mutations, ethnic “background
variations” also affect penetrance and expressivity of genetic
variants, further complicating genotype-phenotype predictions
(Pan et al., 2012; McNally et al., 2015). Population-specific data
have been reported in online databases of sequence variants,
including those found in the NCBI, 1000 Genomes Project,
and Exome Aggregation Consortium (ExAC). Allele frequencies
of sarcomeric genes encoding β-myosin heavy chain, myosin
binding protein C, and titin have been shown to differ among
distinct ethnic groups (Golbus et al., 2012). Importantly, this
study also reported that pathogenic variation in these genes
was significantly higher than expected in the 1000 Genomes
Database. This underscores the need for more comprehensive
sequencing and screening of at-risk populations.
Population genetics studies on SA have been scarce, despite
a well-documented increased risk of heart disease (Anand et al.,
2000; Yusuf et al., 2004; Fernando et al., 2015). Southeast Asian
genetic diversity is significantly underrepresented in the 1000
Genomes Project (Lu and Xu, 2013). Chambers et al. provided
the first comprehensive genetic study of SA, performing whole-
genome sequencing of 168 subjects (Chambers et al., 2014).
Prior to the publication of this study in 2014, a mere two
genomes had been used as references for the entire South
Asian population, which complicated predictions of disease
susceptibility (Kitzman et al., 2011; Gupta et al., 2012). In a
recent study, the Exome Aggregation Consortium cited the
underrepresentation of certain populations in previous genomic
databases, notably Latinos and SA (Lek et al., 2016). Certain
South Asian specific polymorphisms have been studied, but are of
limited use due to small sample sizes that have very little statistical
power (Dodani et al., 2012; Yadav et al., 2013). Extraction of
meaningful information from raw datasets in online databases
and association with clinical presentation is undoubtedly a
necessary next step in the development of personalized medicine
(Lek et al., 2016). It seems fitting that more genetic studies should
be geared toward SA in order to study inherited treatable diseases
like HCM. GenomeAsia 100k is a non-profit consortium aiming
to generate Asian-specific genomic data. Importantly, the initial
phase includes sequencing 10,000 reference genomes for all major
ethnic groups within the Asian umbrella. As the name suggests,
their ultimate goal is to generate genetic, microbiomic, clinical,
and phenotypic data for 100,000 Asian genomes. If successfully
completed, this genetic data will hugely contribute to future
research and clinical efforts.
MOLECULAR GENETICS OF HCM
HCM is inherited in an autosomal dominant manner, and most
of the 1400+ variants associated with HCM encode sarcomeric
proteins (Brouwer et al., 2011; Schlossarek et al., 2011). Nine
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sarcomeric genes carry the majority of HCM-related mutations
and encode the proteins: β-myosin heavy chain (MYH7),
cardiac myosin binding protein C (MYBPC3), cardiac troponin
T (TNNT2), cardiac troponin I (TNNI3), α-tropomyosin
(TPM1), regulatory myosin light chain (MYL2), essential myosin
light chain (MYL3), cardiac α-actin (ACTC), and cardiac
troponin C (TNNC1). The arrangement and interaction of
proteins in the cardiac sarcomere is illustrated in Figure 3.
Another group of mutations can be found in the genes encoding
sarcomeric Z-disc proteins such as muscle LIM protein, α-
actinin, or telethonin (Knöll et al., 2010), but these are outside the
scope of this review. The number of studies focusing on HCM-
associated mutations in SA is disproportionately small when
considering the size of this population and collective increased
risk of CVD. To date, only 21 of the published variants associated
with HCMhave been documented in SA. These variants are listed
in Table 1. In following with the Pareto principle (also known as
the 80–20 rule), the majority of adverse HCM events comes from
only a few central causes. In the case of HCM, over 80% of known
HCM-associated mutations occur inMYBPC3 andMYH7 alone,
while an additional 10% come fromTNNT2 andTNNI3 (McNally
et al., 2015). Thus, at least 90% of known HCM cases originate
from four sarcomeric genes. The involvement of these four genes
in the development of HCM is discussed below.
THICK FILAMENT MUTATIONS
ASSOCIATED WITH HCM
The thick filament of the sarcomere consists of bundles of
myosin molecules, which form a cylindrical backbone as seen
in Figure 3. The bipolar head domains project radially to
interact with the thin filament during contraction (Spudich,
2014). Although attractive, the idea that myosin mutations
causing hypercontractility lead to HCM and those causing
hypocontractility lead to DCM has not been definitively
established (Spudich, 2014). However, changes in calcium
sensitivity (higher in HCM, decreased in DCM) have been
discussed, and a direct link between calcium sensitivity, which
induces heart growth via tension generation, and HCM has
recently been established (Davis et al., 2016).
MYH7 Mutations
MYH7 encodes cardiac β-myosin heavy chain (β-MHC), which
is the major part of the thick filament of the sarcomere.
The intrinsic ATPase activity of the catalytic domains of
β-MHCprovides the energy for sarcomeric contraction.Missense
mutations in the globular head domain of β-MHC tend to
produce HCM because they prevent interaction with actin, which
is necessary for proper sarcomeric contraction (Volkmann et al.,
2007). The lever-likemyosin converter domain and globular head
region show significant genetic constraint, andmutations in these
regions are associated with severe forms of HCM (Homburger
et al., 2016). The combination of normal and mutant or “poison
peptide” causes detrimental structural and functional effects in
the sarcomere (Brouwer et al., 2011). To date, 289 mutations
have been found in MYH7 that are thought to produce HCM,
and this gene comprises 40% of the genetic profile of the disease
(Morimoto, 2008; Stenson et al., 2014). Only eight of these
variants have been published in SA. Mutations in MYH7 are
associated with early-onset and extensive LVH (Roma-Rodrigues
and Fernandes, 2014), and clinically are associated with an
increased risk of atrial fibrillation, SCD and heart failure (Wang
et al., 2008; Lopes et al., 2013a). In the Indian population, it has
been predicted that the frequency of MYH7 mutations may be
lower than their MYBPC3 counterpart, although validation in a
large sample is required for confirmation (Morimoto, 2008).
Due to its clinical severity, the MYH7-R403Q variant was
the first HCM-causing mutation to be discovered (Geisterfer-
Lowrance et al., 1990; Nag et al., 2015). This mutation, which
affects the “cardiomyopathy loop” at the interface of actin and
myosin (Marian, 2002; Volkmann et al., 2007) is associated with
severe LVH and nearly 100% penetrance of SCD at a young
age (Lopes et al., 2013a). Studies on this variant have been
particularly helpful in studying both loss-of-function and gain-
of-function mutations associated with HCM. Loss-of-function
mutations result in reduced contractile force (Nag et al., 2015),
while gain-of-function mutations generate supraphysiological
force (Seidman and Seidman, 2001; Moore et al., 2012). The
diverse manifestations of the same mutation on sarcomere
biomechanics emphasizes the need to fully characterize the
signaling pathways involved in disease development and develop
specialized therapies.
MYBPC3 Mutations
MYBPC3 encodes the cardiac isoform of myosin binding protein
C (cMyBP-C). cMyBP-C is a thick filament-associated protein
that acts as a tether for the myosin head domain and also
associates with actin and titin. cMyBP-C is found in the C-zone
of the sarcomere and has both structural and regulatory roles in
sarcomere assembly. Mutations inMYBPC3 typically take longer
tomanifest than those inMYH7, presenting inmiddle age or later
and after the typical reproductive age (Wang et al., 2008). To
date, around 346 MYPBC3 mutations have been found that are
associated with HCM, and comprise at least 40% of the genetic
profile of the disease (Morimoto, 2008; Stenson et al., 2014). Of
these 346, a mere 5 have been published in South Asian subjects.
As opposed to MYH7 mutations, the majority of those affecting
MYBPC3 result in abnormal truncation of the C-terminus of
cMyBP-C (Kuster and Sadayappan, 2014). The degradation of
these aberrant expression products is thought to contribute to
HCM via haploinsufficiency, i.e., inadequate amounts of the
normal protein product (Brouwer et al., 2011).
Perhaps the most well-cited example of a region-specific
polymorphism in SA is a 25-bp deletion in MYBPC3
(MYBPC3∆Int32) (Waldmüller et al., 2003; Dhandapany
et al., 2009). The genetic heterogeneity of HCM, background
genetic noise, and cost of sequencing make screening impractical
for the general population (Kapplinger et al., 2014). However, the
prevalence of the MYBPC3∆Int32 variant is at least 4% in SA but
virtually non-existent in Caucasians. The exclusivity of this allele
to South Asian descendants makes genetic screening effective
and practical for this population (Kuster and Sadayappan, 2014).
The 25-bp deletion from intron 32 of MYBPC3 causes a reading
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FIGURE 3 | Protein constituents and arrangement of the cardiac sarcomere. The majority of HCM cases are the result of abnormal sarcomeric proteins. The
sarcomere is the functional unit of striated muscle. The visible striations or bands of the cardiac sarcomere are due to the overlap of thin and thick filaments. The main
constituents of the thick filament are β-myosin heavy chain, myosin binding protein C, titin, and the regulatory and essential light chains. Troponin T (TnT), troponin I
(TnI), troponin C (TnC), tropomyosin, and actin comprise the thin filament of the sarcomere. Titin is a giant protein that connects the thick filament to the edge of the
sarcomere and creates passive tension in resting muscle.
frameshift in translation, and the aberrant protein product
cMyBP-CC10mut lacks exon 33 and includes abnormal parts of
exon 34 and part of the 3′ untranslated region (Waldmüller
et al., 2003; Dhandapany et al., 2009). The altered C10 domain
cannot normally link cMyBP-C to the myosin heavy chain and
leads to contractile dysfunction (Kuster et al., 2015). Double
heterozygotes, or patients carrying both the MYBPC3∆Int32
mutant allele and another mutant allele in MYH7-E927del,
seem to have a more severe HCM phenotype suggesting an
additive effect of these mutations (Waldmüller et al., 2003).
Systematic studies are currently underway at various laboratories
to determine if the MYBPC3∆Int32 variant is sufficient to cause
HCM.
THIN FILAMENT MUTATIONS
ASSOCIATED WITH HCM
α-tropomyosin, along with the troponins T, I, and C form
the troponin-tropomyosin complex that regulates contraction in
striatedmuscle. As seen in Figure 3, this complex is interdigitated
with actin and winds together to form the thin filament of the
sarcomere. This regulatory complex prevents strong association
between the thick and thin filament in low Ca2+ and ATP
conditions (McNally et al., 2015). Thin filament mutations
typically increase Ca2+ sensitivity of tension development
(Ashrafian et al., 2011) or uncouple Ca2+ sensitivity from
phosphorylation (Papadaki et al., 2015).
TNNT2 Mutations
The connection between TNNT2, the gene encoding the cardiac
isoform of troponin T (TnT), andHCMwas first reported in 1994
(Thierfelder et al., 1994). TNNT2 variants account for about 5%
of HCM cases (Morimoto, 2008). TnT mutants have been linked
to increased risk of SCD at a young age (Marian, 2002; Lopes
et al., 2013a) but typically patients carrying these variants exhibit
little to no hypertrophy (Chandra et al., 2005). TnT mutants are
thought to alter cross-bridge kinetics, thereby limiting shortening
velocity at maximal Ca2+ activation and increasing the energetic
cost of contraction (Sweeney et al., 1998). In mice, degree of
Ca2+ sensitization from mutations in TnT were found to directly
correspond to arrhythmic risk and were reduced with the Ca2+
desensitizer Blebbistatin (Baudenbacher et al., 2008). To date, 43
HCM-related mutations in TNNT2 have been documented in the
general population (Morimoto, 2008; Stenson et al., 2014). In SA,
3 TNNT2 variants have been published that are associated with
HCM, as seen in Table 1.
TNNI3 Mutations
TNNI3, which encodes troponin I, was first linked to HCM in
1997 (Kimura et al., 1997). TNNI3 mutations make up about
5% of the genetic profile of HCM (Morimoto, 2008). 38 HCM-
related mutations in TNNI3 are known, and 4 of these have been
documented in SA (Stenson et al., 2014) as can be seen inTable 1.
Recently, mutations in the highly conserved inhibitory peptide
region of troponin I were found to alter myofilament Ca2+
sensitivity (Westfall et al., 2002). Mutations in this important
Frontiers in Physiology | www.frontiersin.org 6 October 2016 | Volume 7 | Article 499
Kraker et al. Hypertrophic Cardiomyopathy in South Asian Descendants
TABLE 1 | Sarcomeric gene variants associated with HCM in South Asians.
Gene Variant Pathogenicity status References
MYH7
c.2221G > T Arg712Leu N/A Sakthivel et al., 2000; Waldmüller et al., 2003
1E927 N/A Waldmüller et al., 2003
NM_000257.3(MYH7):c.2609G > A (p.Arg870His)
rs36211715
Pathogenic/Likely pathogenic Tanjore et al., 2006; Bashyam et al., 2007
NM_000257.3(MYH7):c.1544T > C (p.Met515Thr)
rs863224900
Likely pathogenic Rai et al., 2009
NM_000257.3(MYH7):c.1816G > A (p.Val606Met)
rs121913627
Pathogenic / Likely pathogenic Rai et al., 2009
NM_000257.3(MYH7):c.2146G > A (p.Gly716Arg)
rs121913638
Conflicting interpretations of
pathogenicity
Rai et al., 2009
NM_000257.3(MYH7):c.2686G > A (p.Asp896Asn)
rs606231340
Pathogenic Rani et al., 2014; Selvi Rani et al., 2015
I524K N/A Selvi Rani et al., 2015
MYBPC3
NM_000256.3(MYBPC3):c.3641G > A (p.Trp1214Ter)
rs730880597
Pathogenic Bashyam et al., 2012
D570fs N/A Tanjore et al., 2008
NM_000256.3 (MYBPC3):c.2308G > A (p.Asp770Asn)
rs36211723
Pathogenic/Likely pathogenic Tanjore et al., 2008
NM_000256.3 (MYBPC3):c.3815-1G > A rs397516044 Pathogenic/Likely pathogenic Waldmüller et al., 2003; Tanjore et al., 2008;
Dhandapany et al., 2009; Srivastava et al.,
2011; Kuster et al., 2015
NM_000256.3 (MYBPC3):c.1357_1358delCC
(p.Pro453Cysfs) rs727503203
Pathogenic Waldmüller et al., 2003
TNNT2
NM_001001430.2 (TNNT2):c.430C >T (p.Arg144Trp)
rs483352832
Conflicting interpretations of
pathogenicity
Rani et al., 2012a, 2014
g.5857 A28V N/A Rani et al., 2012a
NM_001001430.2 (TNNT2):c.318C > G (p.Ile106Met)
rs3729547
Uncertain significance Rani et al., 2012a
TNNI3
g. 2601 C > G P82R N/A Rani et al., 2012b
g. 4019 G > A R98Q N/A Rani et al., 2012b; Ramachandran et al., 2013
NM_000363.4 (TNNI3):c.422G > A (p.Arg141Gln)
rs397516347
Pathogenic/Likely pathogenic Rani et al., 2012b; Ramachandran et al., 2013
NM_000363.4 (TNNI3):c.485G > A (p.Arg162Gln)
rs397516354
Pathogenic/Likely pathogenic Rani et al., 2012b; Ramachandran et al., 2013
TPM1
NM_001018005.1 (TPM1):c.644C > T (p.Ser215Leu)
rs199476316
Conflicting interpretations of
pathogenicity
Gupte et al., 2015; Rangaraju et al., 2012; Selvi
Rani et al., 2015
PubMed published variants have been listed with Human Genome Variation Society (HGVS) nomenclature (noted as NM_XXXX), Single Nucleotide Polymorphism Database (dbSNP)
Reference SNP cluster ID (noted as rsXXXX), and ClinVar pathogenicity status where possible. For published variants without a ClinVar reference, N/A is listed under pathogenicity
status. Intronic variants and those classified as benign or likely benign have not been included in the table. None of these mutations were reported to be coexistent with other mutations
that could confound pathogenicity status of the listed variant.
regulatory region are thought to produce increased tension at
physiological Ca2+ levels and prevent relaxation.
NON-SARCOMERIC MUTATIONS
ASSOCIATED WITH HCM
Non-sarcomeric genes are also involved in HCM, and some
researchers have proposed that the disease should be reclassified
into sarcomeric and non-sarcomeric because pathophysiology
and prognosis differ significantly between these groupings
(Olivotto et al., 2011; McNally et al., 2015). The variable
penetrance and expressivity in HCM means that the same
mutation may cause severe disease in one person, but a
completely normal phenotype in another (Tanjore et al., 2010).
Genotypically positive but phenotypically negative patients have
perplexed researchers, and suggest a role of modifier genes in
clinical outcomes (García-Honrubia et al., 2016).
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This review will focus on a well-documented angiotensin-1
converting enzyme (ACE) polymorphism in SA that contributes
to the HCM phenotype in a dose-dependent manner (Rai et al.,
2008). The insertion allele (I) corresponds to the presence of
a 287-bp transposable Alu element repeat, and the deletion
allele (D) corresponds to the absence of this sequence from
the ACE gene (Marian, 2002). LVH was most severe in
patients with the DD genotype, which corresponds to higher
plasma and tissue ACE levels. LVH was less pronounced in
heterozygous ID individuals and least severe in II individuals,
who were found to have less circulating ACE (Marian, 2002).
Long-term activation of components in the renin-angiotensin-
aldosterone system such as ACE is thought to lead to
vascular remodeling and hypertrophy seen in HCM. However,
significant inconsistencies have been reported regardingACE I/D
polymorphisms in HCM patients (Yang et al., 2013). To avoid
limitations due to genetic heterogeneity and small sample size,
large-scale studies or of ACE I/D polymorphisms in genetically
distinct groups are necessary (Kolder et al., 2012; Luo et al.,
2013).
SECONDARY HCM CAN BE A RESULT OF
EXTRACARDIAC DISEASE
Patients with extracardiac disease can also present with LVH
similar to that seen in HCM, and these are listed in Table 2.
Many of these diseases present with other obvious systemic
findings, allowing early differential diagnosis (Roma-Rodrigues
and Fernandes, 2014). A notable exception is milder forms of
Fabry disease, which has often been inaccurately diagnosed as
HCM with the same prevalence as some sarcomeric mutations
(Sachdev et al., 2002). This is significant because Fabry disease is
treatable with enzyme replacement therapy, while the chamber
remodeling associated with HCM is currently irreversible. For
this reason, mutations in the genes causing Fabry disease and
Danon disease are often included in genetic test panels for HCM.
Of these systemic diseases, only 6 have been documented in
SA, as shown in Table 2. This further underscores the need
to note subjects’ ancestry when performing genetic testing and
the relevance of this information to the scientific community.
The number of mitochondrial disorders causing phenocopies of
HCM is too extensive for this review and have not been included
in Table 2.
MOLECULAR MECHANISMS UNDERLYING
THE DEVELOPMENT OF HCM
On the sarcomeric level, several mechanisms are thought
to link the genotype to the clinical phenotype of HCM.
Increased myofilament Ca2+ sensitivity is believed to be pro-
arrhythmogenic, although the exact molecular mechanism(s)
involved remain(s) unclear. Altered Ca2+ handling, inefficient
energy utilization, and increased mechanical stretch may play a
role in the development of anatomical and functional changes
observed in hearts with HCM (Huke and Knollmann, 2010;
Ashrafian et al., 2011). Stabilization and prolongation of the Ca2+
transient would pathologically activate intracellular signaling
pathways and diminish relaxation, contributing to electrical
conduction abnormalities and diastolic dysfunction (Roma-
Rodrigues and Fernandes, 2014). A predicted consequence of
altered Ca2+ sensitivity is inefficient energy usage, including
increased cross-bridge turnover, increased ATPase activity,
and mitochondrial energetic abnormalities causing oxidative
stress (Ashrafian et al., 2011; Brouwer et al., 2011). Energy
and calcium are intrinsically linked to muscle mechanics
due to excitation-contraction coupling; thus, force production
of myofilaments will be abnormally increased as a result
of Ca2+ sensitization. Therapeutic strategies are currently
being explored which reinstate normal Ca2+ homeostasis,
lower Ca2+ sensitivity, and increase efficiency of energy
utilization (Brouwer et al., 2011). A recent breakthrough
showed that increased Ca2+ sensitivity of troponin C causes
prolonged myofilament tension, concentric sarcomeric addition,
and hypertrophy consistent with HCM (Davis et al., 2016).
DCM was linked to decreased Ca2+ sensitivity in the same
study.
CURRENT EFFORTS TOWARD PRECISION
MEDICINE FOR HCM
The current technologies outlined in this section are still in their
infancy, and require much optimization in order to be developed
into clinical therapies. However, the existence of HCM-
associated variants unique to SA represents a largely unexplored
opportunity to developmolecular models for cardiac disease. The
vast size of this population makes application of these models
to clinical treatments a logical and potentially lucrative next
step.
Reprogramming of Cardiomyocytes
Adult somatic cells can be reprogrammed using sets of
transcription factors to generate human induced pluripotent
stem cells (iPSCs) and then functional cardiomyocytes
(Kamdar et al., 2015), offering researchers the opportunity
to study the molecular mechanisms of CVD and myocardial
tissue regeneration following ischemic injury. iPSC-derived
cardiomyocytes have been successfully used to study systemic
diseases that present with HCM, including Pompe disease
(Huang et al., 2011) and LEOPARD syndrome (Carvajal-Vergara
et al., 2010).
The pathogenic effects of MYH7 and MYBPC3 mutations
have been demonstrated using iPSC-derived cardiomyocytes
(Ross et al., 2016). Lan and colleagues administered calcium
blockers to iPSC-derived cardiomyocytes from HCM patients
harboring the MYH7-R663H mutation (Lan et al., 2013). These
drugs seemed to prevent structural and functional abnormalities
typical of HCM, suggesting that their use in prophylaxis warrants
investigation. Han and colleagues similarly examined theMYH7-
R442G mutation (Han et al., 2014). They performed whole-
transcriptome sequencing and documented an upregulation in
gene expression in various cell proliferation signaling pathways
including Wnt/β-catenin, Calcineurin-NFAT, and FGF that
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TABLE 2 | Systemic diseases that present with secondary HCM.
Type of disease Name of disease Gene Gene product References
Lysosomal storage
disease
Fabry disease GLA α-Galactosidase Wani et al., 2016; Sachdev et al.,
2002
Glycogen storage
disease (GSD)
Pompe disease (GSD type II) GAA α-1,4-Glucosidase Lim et al., 2014; Van der Ploeg
et al., 1989; Raju et al., 2010;
Jegadeeswari et al., 2012
Glycogen storage
disease
Danon disease (GSD type IIb) LAMP2 LAMP2 Endo et al., 2015
Glycogen storage
disease
Cori’s disease (GSD type IIIa) AGL Amylo-1,6-glucosidase Lee et al., 1997; Lucchiari et al.,
2002
Glycogen storage
disease
Anderson’s disease (GSD type IV) GBE1 Amylo-1,4-1,6-
transglucosidase
Aksu et al., 2012
Neuromuscular disorder Friedreich’s ataxia FXN Frataxin, mitochondrial
protein
Kumari and Usdin, 2009
Neuromuscular disorder Myotonic muscular dystrophy DMPK Myotonic dystrophy
protein kinase
Lau et al., 2015
RASopathy Noonan’s syndrome RIT1 Rit1 Aggarwal et al., 2011
RASopathy LEOPARD syndrome (noonan syndrome
with multiple lentigines)
PTPN11 SHP2 Jayaprasad and Madhavan, 2015
RAF1 Protein tyrosine
phosphatase
BRAF
Metabolic storage
disorder
Wolff-Parkinson-white syndrome with
HCM
PRKAG2 γ2 regulatory subunit of
AMP-activated protein
kinase (AMPK)
Sidhu and Roberts, 2003;
Bashyam et al., 2012
Lipodystrophy Congenital generalized lipodystrophy
(CGL) types 1–4 Berardinelli-Seip
syndrome
1. AGPAT2
2. BSCL2
3. CAV1
4. PTRF
1. 1-acylglycerol-3-
phosphate
O-acyltransferase 2
2. Seipin
3. Caveolin
4. Polymerase I,
transcript release factor
Lupsa et al., 2010; Rahman et al.,
2013
Mitochondrial disorders Mitochondrial DNA
Various: MELAS, MERRF, CPEO, NARP,
Leigh Syndrome, etc.
Finsterer and Kothari, 2014
Secondary HCM refers to hypertrophic cardiomyopathy that originates from another disease, the origin of which is outside of the heart. References in bold typeface correspond to
PubMed published cases documented in South Asians.
are thought to contribute to the disease phenotype. Tanaka
and colleagues investigated how Endothelin-1, a circulating
vasoconstrictive peptide, induced the HCM phenotype in iPSC-
derived cardiomyocytes containing theMYBPC3-G999-Q1004del
mutation (Tanaka et al., 2014). Lan et al. specified their proband’s
ethnicity as African-American, but the two studies assessing
MYH7 variants lack ethnicity information. In vivo direct cardiac
reprogramming of somatic cells into cardiomyocytes is a
potential offshoot of current reprogramming techniques but has
not yet been tested in humans (Sadahiro et al., 2015). For HCM
in particular, the possibility of converting cardiac fibroblasts
into functional cardiomyocytes could theoretically ameliorate
hypertrophy and improve diastolic function. As reprogramming
technology advances, these techniques could offer a renewable
source of cardiomyocytes and deliver medicine individually
tailored to each patient (Chen and Qian, 2015; Tanaka et al.,
2015).
Variant Databases
Next generation sequencing (NGS) protocols for screening
cardiomyopathies have been successfully developed (Gómez
et al., 2014), and they will continue to uncover new variants.
Improved methods of distinguishing between benign and
pathogenic mutations will enhance the accuracy of risk
prediction of genetic screens for HCM (Kapplinger et al., 2014).
Further, combination of gene expression analysis and clinical
phenotypic assessments are necessary to uncover unknown
modifier genes in HCM patients (Han et al., 2014). The
development of online databases for HCM variants could aid
physicians in the timing and implementation of electrical or
surgical treatment options (McNally and Puckelwartz, 2015). As
mentioned in the preceding sections, inclusion of ethnicity data
in such databases has important genetic consequences and thus is
clinically relevant. The future of personalized medicine will rely
heavily on such collaborative efforts.
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Gene Editing Technology
Of the cardiovascular diseases, primary inherited
cardiomyopathies such as HCM are perhaps the strongest
candidates for gene editing technologies (Strong and Musunuru,
2016). Directed nucleases such as Transcription Activator-Like
Effector Nucleases, Zinc Finger Nucleases (TALENs), and
Clustered, Regularly Interspaced, Short Palindromic Repeats
(CRISPR) and CRISPR-associated 9 (Cas9) systems allow for
specific editing of individual gene mutations. This CRISPR/Cas9
system is the current frontrunner of these gene modification
technologies and has the potential to facilitate causation
studies, by both creating and correcting a specific mutation
and documenting the associated phenotype (Han et al., 2014).
This technology promises to provide researchers with more
accurate model for studying cardiomyopathies, circumventing
the inherent ethical issues when studying human subjects
(Waddington et al., 2016). To date, the CRISPR/Cas9 system
has been used to successfully engineer cardiomyopathy into in
zebrafish and mice models, and is currently being applied to
larger animals such as pigs and non-human primates (Duncker
et al., 2015).
The CRISPR/Cas9 system has been used to edit the genomes
of mice with Duchenne muscular dystrophy, an X-linked
genetic disorder that presents with cardiomyopathy. The normal
muscle phenotype in mice embryos was rescued following
correction of the mutant dystrophin (Dmd) gene (Long et al.,
2014). Considerable shortcomings of this technology include
the variable correction efficiency and the introduction of
mutagenesis at an incorrect but sequentially similar location
(Strong andMusunuru, 2016). Currently there are no established
techniques that can identify off-target mutagenesis. However,
despite these concerns, CRISPR/Cas9-mediated genome editing
is an exciting frontier in the genetic realm. In theory,
it could eliminate inherited genetic disorders such as the
cardiomyopathies altogether.
Small-Molecule Inhibitors
The recently developed small myosin ATPase inhibitor MYK-
461 was found to reduce sarcomeric contractility, LVH, myocyte
disarray, and fibrosis in mice with HCM (Green et al., 2016).
Although MYK-461 has huge potential as a therapeutic agent, it
is not effective at reversing myocyte disarray and fibrosis once
substantial hypertrophy has developed (Green et al., 2016). This
underscores the need for expanded genetic screening in at-risk
populations in order to administer earliest such preventative
treatments. Pharmacologic treatments typically relieve heart
failure symptoms without altering disease progression (Green
et al., 2016). However, in a recent study, the calcium channel
blocker Diltiazem used to treat hypertension and chest pain was
shown to prevent reduction in left ventricular chamber size in
HCM patients carrying MYBPC3 mutations (Ho et al., 2015).
This observed attenuation of HCM development is promising,
and the drug could be used to treat at-risk family members before
they notice the functional heart failure symptoms associated
reduced cardiac output. Continued refinement of small-molecule
inhibitors to arrest or even reverse hypertrophy, myocyte
disarray, and fibrosis will likely aid in untangling the complex
cellular mechanisms involved HCM development (Frey et al.,
2012).
CONCLUSIONS
The failure of risk factors to explain the increased prevalence
of CVD in SA suggests a strong genetic causation that needs
active characterization. For HCM in particular, it is imperative
that SA receive higher priority for systematic genome-wide
studies. Such studies will uncover population specific variants
contributing to susceptibility, and could lead to better diagnosis
and management of HCM. By taking advantage of novel
technologies such as NGS, human iPSC derived cardiomyocytes,
and gene editing nucleases, it is hoped that we will be able to
significantly improve the lives of patients affected by genetic heart
failure. It is essential that novel genomics technologies are used
to reduce health disparities among marginalized and minority
groups rather than perpetuate them (Rotimi and Jorde, 2010).
Efforts such as those led by GenomeAsia100k will provide the
necessary genetic data for future discovery.
Genetic variants, molecular mechanisms, and clinical
phenotypes of HCM vary on a patient-by-patient basis. The
Precision Medicine Initiative announced by President Obama
in 2015 aims to personalize the current “one-size-fits-all” model
of healthcare from the level of diagnosis all the way to delivery.
In this article, we underscore the relevance of ethnicity data
to genetic studies in particular, and stress that future studies
specifically address the very large yet largely neglected South
Asian population. The Sarcomeric Human Cardiomyopathy
Registry (SHaRe) is an exciting interdisciplinary model that
brings together geneticists and cardiologists to share and develop
longitudinal, personalized data for patients with HCM andDCM.
Although these efforts havemostly been undertaken in developed
countries (Fox, 2015), this review has emphasized the need to
address highly populated and underserved regions such as South
Asia. Considering the genetic and clinical heterogeneity of the
disease and its potential treatability, established cardiovascular
centers of excellence provide the best possible treatment for
HCM patients (Gersh et al., 2011; Maron et al., 2014). The
Amrita Institute of Medical Sciences and Research in India has
undertaken the task of becoming such a center, and if successful
is expected to have dramatic impacts on HCM healthcare
delivery in the South Asian subcontinent (Maron, 2015).
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